{
  "main_header": {
    "sid": 576337,
    "name": "Rekvina Labs",
    "stock_name": "Rekvina Labs",
    "full_name": "Rekvina Labs Ltd",
    "name_url": "stocks-analysis/rekvina-labs",
    "exchange": 0,
    "exchangecode": "",
    "country_id": 34,
    "currency": "INR",
    "cmp": "36.72",
    "chg": "0.00",
    "chgp": "0.00%",
    "dir": 0,
    "prev_price": "36.72",
    "mcapval": "23.00 Cr",
    "mcap": "",
    "scripcode": 526075,
    "symbol": "",
    "ind_name": "Pharmaceuticals & Drugs",
    "ind_code": 4,
    "indexname": "India SENSEX",
    "isin": "INE092O01028",
    "curr_date": "Jun 17",
    "curr_time": "",
    "bse_nse_vol": 51,
    "exc_status": "Active",
    "traded_date": "Jun 17, 2026",
    "traded_date_str": "2026 06 17",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-registerF-score-header",
    "is_blur_url": "https://marketsmojo.motilaloswaluat.com/MOSL-Landingstocks-analysis/rekvina-labs-576337-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [],
    "total": 0,
    "sid": "576337",
    "stock_news_url": "https://marketsmojo.motilaloswaluat.com/news/rekvina-labs-576337"
  },
  "announcements": [
    {
      "caption": "Financial Results For Quarter Ended & Year Ended On March 31 2026.",
      "datetime": "21-May-2026",
      "details": "Standalone Audited Financial Results for the Quarter ended & Year ended on March 31 2026 along with statement of Assets & Liabilities Cash Flow statement & unmodified Audit Report.",
      "source": "BSE"
    },
    {
      "caption": "Board Meeting Outcome for Outcome Of Board Meeting Held On 21St May 2026",
      "datetime": "21-May-2026",
      "details": "Pursuant to Reg 33 read with Part A of Schedule III of SEBI (LODR) Regulation 2015 we hereby submitting the following: 1. Standalone Audited Financial Results for the Quarter ended and Year ended on March 31 2026 along with Assets & Liability Statement & Cash Flow Statement with Independent Auditor Report 2. Declaration of Auditor Report with unmodified Opinion pursuant to Reg 33 (3)(d) of Listing Regulations signed by Mr. Amit Shah Director of the Company.",
      "source": "BSE"
    },
    {
      "caption": "Board Meeting Intimation for Consider And Approve Financial Result For The QTR 4",
      "datetime": "18-May-2026",
      "details": "Rekvina Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 21/05/2026 inter alia to consider and approve Financial Result for the Quarter and Year ended 31.03.2026",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "No <strong>Dividend</strong> history available",
      "data": []
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "",
      "data": [
        {
          "txt": "Rekvina Labs Ltd has announced <strong>5:10</strong> stock split, ex-date: 30 Apr 14",
          "dt": "2014-04-30",
          "middle_text": "Split"
        }
      ]
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

No Recent News for the Company

View All News